PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33715419-2	2021	Materials & methods: Bioinformatic docking of candidate molecules featuring a wide range of carboxylic acid bioisosteres into complex with GPR40 was performed using TAK-875 and GW9508 templates.	GW9508	177-183	free fatty acid receptor 1	Homo sapiens	139-144
33376857-0	2020	GPR120 Agonist GW9508 Ameliorated Cellular Senescence Induced by ox-LDL.	GW9508	15-21	free fatty acid receptor 4	Homo sapiens	0-6
33009637-4	2021	GPR120 agonist GW9508 activated the GPR120 pathway.	GW9508	15-21	free fatty acid receptor 4	Homo sapiens	0-6
33009637-4	2021	GPR120 agonist GW9508 activated the GPR120 pathway.	GW9508	15-21	free fatty acid receptor 4	Homo sapiens	36-42
33376857-8	2020	Typically, 100 mug/mL of ox-LDL- induced 35.2% LDH release, which was reduced to 16.9% by 50 muM GW9508, the agonist of GPR120.	GW9508	97-103	free fatty acid receptor 4	Homo sapiens	120-126
33376857-10	2020	Furthermore, we found that GW9508 ameliorated ox-LDL-induced endothelial cell cycle arrest at the G0/G1 phase and the expression of key senescence proteins, including p53 and plasminogen activator inhibitor-1(PAI-1).	GW9508	27-33	tumor protein p53	Homo sapiens	167-170
33376857-10	2020	Furthermore, we found that GW9508 ameliorated ox-LDL-induced endothelial cell cycle arrest at the G0/G1 phase and the expression of key senescence proteins, including p53 and plasminogen activator inhibitor-1(PAI-1).	GW9508	27-33	serpin family E member 1	Homo sapiens	175-208
33376857-10	2020	Furthermore, we found that GW9508 ameliorated ox-LDL-induced endothelial cell cycle arrest at the G0/G1 phase and the expression of key senescence proteins, including p53 and plasminogen activator inhibitor-1(PAI-1).	GW9508	27-33	serpin family E member 1	Homo sapiens	209-214
33376857-11	2020	Mechanistically, we showed that GW9508 promoted ox-LDL-induced transcriptional factor NF-E2-related factor 2 (NRF2) (increase by 47.3%) translocation into the nucleus.	GW9508	32-38	NFE2 like bZIP transcription factor 2	Homo sapiens	86-108
33376857-11	2020	Mechanistically, we showed that GW9508 promoted ox-LDL-induced transcriptional factor NF-E2-related factor 2 (NRF2) (increase by 47.3%) translocation into the nucleus.	GW9508	32-38	NFE2 like bZIP transcription factor 2	Homo sapiens	110-114
33376857-12	2020	The effect of GW9508 is dependent on its receptor GPR120, the blockage of which by its specific antagonist, AH7614, abolished the antisenescence effect of GW9508.	GW9508	14-20	free fatty acid receptor 4	Homo sapiens	50-56
33376857-12	2020	The effect of GW9508 is dependent on its receptor GPR120, the blockage of which by its specific antagonist, AH7614, abolished the antisenescence effect of GW9508.	GW9508	155-161	free fatty acid receptor 4	Homo sapiens	50-56
32243091-4	2020	In this study, we found for the first time that stimulation of GPR120 by its agonist GW9508 elevated the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 in THP-1 macrophage-derived foam cells and Raw264.7 macrophages, and promoted ABCA1- and ABCG1-mediated cholesterol efflux and reduced cellular cholesteryl ester content as well.	GW9508	85-91	free fatty acid receptor 4	Homo sapiens	63-69
32243091-4	2020	In this study, we found for the first time that stimulation of GPR120 by its agonist GW9508 elevated the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 in THP-1 macrophage-derived foam cells and Raw264.7 macrophages, and promoted ABCA1- and ABCG1-mediated cholesterol efflux and reduced cellular cholesteryl ester content as well.	GW9508	85-91	ATP binding cassette subfamily A member 1	Homo sapiens	119-161
32243091-4	2020	In this study, we found for the first time that stimulation of GPR120 by its agonist GW9508 elevated the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 in THP-1 macrophage-derived foam cells and Raw264.7 macrophages, and promoted ABCA1- and ABCG1-mediated cholesterol efflux and reduced cellular cholesteryl ester content as well.	GW9508	85-91	ATP binding cassette subfamily G member 1	Homo sapiens	166-171
32243091-4	2020	In this study, we found for the first time that stimulation of GPR120 by its agonist GW9508 elevated the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 in THP-1 macrophage-derived foam cells and Raw264.7 macrophages, and promoted ABCA1- and ABCG1-mediated cholesterol efflux and reduced cellular cholesteryl ester content as well.	GW9508	85-91	GLI family zinc finger 2	Homo sapiens	175-180
32243091-4	2020	In this study, we found for the first time that stimulation of GPR120 by its agonist GW9508 elevated the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 in THP-1 macrophage-derived foam cells and Raw264.7 macrophages, and promoted ABCA1- and ABCG1-mediated cholesterol efflux and reduced cellular cholesteryl ester content as well.	GW9508	85-91	ATP binding cassette subfamily A member 1	Homo sapiens	250-255
32243091-4	2020	In this study, we found for the first time that stimulation of GPR120 by its agonist GW9508 elevated the expression of ATP-binding cassette transporters (ABC) A1 and ABCG1 in THP-1 macrophage-derived foam cells and Raw264.7 macrophages, and promoted ABCA1- and ABCG1-mediated cholesterol efflux and reduced cellular cholesteryl ester content as well.	GW9508	85-91	ATP binding cassette subfamily G member 1	Homo sapiens	261-266
32354273-5	2020	NOX2 KO islets were used to measure total cytosolic calcium and insulin secretion.Results: GW9508 and linoleic acid increased superoxide and H2O2 contents at 5.6 and 8.3 mM of glucose.	GW9508	91-97	cytochrome b-245 beta chain	Rattus norvegicus	0-4
32354273-7	2020	Knockdown of p22phox abolished the increase in superoxide after GW9508 and linoleic acid.	GW9508	64-70	cytochrome b-245 alpha chain	Rattus norvegicus	13-20
32354273-8	2020	No differences in insulin secretion were found between wild type and NOX2 KO islets treated with GW9508 or linoleic acid.Discussion: We report for the first time that acute activation of GPR40 leads to NADPH oxidase activation in pancreatic beta-cells, without impact on insulin secretion.	GW9508	97-103	free fatty acid receptor 1	Rattus norvegicus	187-192
32893672-14	2020	The GW9508 treatment increased leptin levels, without altering UCP-1 downregulation in visceral fat.	GW9508	4-10	leptin	Mus musculus	31-37
32580167-8	2020	We also show that GW9508 and TUG891 rescue the expression of type II collagen and aggrecan by preventing the reduction of SOX9 expression.	GW9508	18-24	SRY-box transcription factor 9	Homo sapiens	122-126
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	242-248	cAMP responsive element binding protein 1	Homo sapiens	112-116
33133087-0	2020	The GPR40 Agonist GW9508 Enhances Neutrophil Function to Aid Bacterial Clearance During E. coli Infections.	GW9508	18-24	free fatty acid receptor 1	Homo sapiens	4-9
33133087-3	2020	In the present study, we demonstrate that GPR40 is upregulated on activated human neutrophils and investigated the functional effects upon treatment with a selective agonist; GW9508.	GW9508	175-181	free fatty acid receptor 1	Homo sapiens	42-47
32347098-0	2020	GPR40 agonist GW9508 ameliorates oxidized LDL-induced endothelial dysfunction via the AMPK/CREB/PGC1alpha pathway.	GW9508	14-20	free fatty acid receptor 1	Homo sapiens	0-5
32347098-0	2020	GPR40 agonist GW9508 ameliorates oxidized LDL-induced endothelial dysfunction via the AMPK/CREB/PGC1alpha pathway.	GW9508	14-20	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	86-90
32347098-0	2020	GPR40 agonist GW9508 ameliorates oxidized LDL-induced endothelial dysfunction via the AMPK/CREB/PGC1alpha pathway.	GW9508	14-20	cAMP responsive element binding protein 1	Homo sapiens	91-95
32347098-0	2020	GPR40 agonist GW9508 ameliorates oxidized LDL-induced endothelial dysfunction via the AMPK/CREB/PGC1alpha pathway.	GW9508	14-20	PPARG coactivator 1 alpha	Homo sapiens	96-105
32347098-5	2020	Interestingly, we found that the activation of GPR40 by its agonist GW9508 ameliorated ox-LDL-induced reduced cell viability of HAECs.	GW9508	68-74	free fatty acid receptor 1	Homo sapiens	47-52
32347098-7	2020	Mechanistically, we found that GW9508 mitigated ox-LDL-induced inactivation of adenosine 5"-monophosphate (AMP)-activated protein kinase alpha (AMPKalpha), however, the blockage of GPR40 by its antagonist GW1100 completely abolished the protective effect of GW9508 on AMPKalpha activation.	GW9508	31-37	free fatty acid receptor 1	Homo sapiens	181-186
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	14-20	cAMP responsive element binding protein 1	Homo sapiens	71-110
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	14-20	cAMP responsive element binding protein 1	Homo sapiens	112-116
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	14-20	cAMP responsive element binding protein 1	Homo sapiens	196-200
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	14-20	PPARG coactivator 1 alpha	Homo sapiens	270-337
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	14-20	PPARG coactivator 1 alpha	Homo sapiens	339-349
32347098-9	2020	Additionally, GW9508 also restored ox-LDL-induced dephosphorylation of cAMP-responsive element-binding protein (CREB), which was also abolished by compound C. Finally, we found that AMPKalpha and CREB participated in mediating the effects of GW9508 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitochondrial homeostasis.	GW9508	242-248	cAMP responsive element binding protein 1	Homo sapiens	71-110
32580167-9	2020	Additionally, we demonstrate that the effects of GW9508 on SOX9 expression are mediated through CREB and that GPR120 is indeed required for this effect.	GW9508	49-55	SRY-box transcription factor 9	Homo sapiens	59-63
32580167-9	2020	Additionally, we demonstrate that the effects of GW9508 on SOX9 expression are mediated through CREB and that GPR120 is indeed required for this effect.	GW9508	49-55	cAMP responsive element binding protein 1	Homo sapiens	96-100
32580167-9	2020	Additionally, we demonstrate that the effects of GW9508 on SOX9 expression are mediated through CREB and that GPR120 is indeed required for this effect.	GW9508	49-55	free fatty acid receptor 4	Homo sapiens	110-116
32580167-10	2020	Thus, agonism of GPR120 by GW9508 might be a potential therapeutic strategy to halt or prevent cartilage degradation.	GW9508	27-33	free fatty acid receptor 4	Homo sapiens	17-23
32431615-8	2020	Besides, HaCaT cells stimulated with LA or GW9508 increased the activity of MMP-9 and the expression of IL-8.	GW9508	43-49	matrix metallopeptidase 9	Homo sapiens	76-81
32606604-5	2020	The purpose of the present study was to determine the impact of the GPR40 agonist GW9508 on AGEs-treated chondrocytes.	GW9508	82-88	free fatty acid receptor 1	Homo sapiens	68-73
32606604-11	2020	Treatment with GW9508 plays a beneficial role in protecting type II Collagen and aggrecan from degeneration by attenuating the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5.	GW9508	15-21	matrix metallopeptidase 3	Homo sapiens	141-146
32606604-11	2020	Treatment with GW9508 plays a beneficial role in protecting type II Collagen and aggrecan from degeneration by attenuating the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5.	GW9508	15-21	matrix metallopeptidase 13	Homo sapiens	148-154
32606604-11	2020	Treatment with GW9508 plays a beneficial role in protecting type II Collagen and aggrecan from degeneration by attenuating the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5.	GW9508	15-21	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	156-164
32606604-11	2020	Treatment with GW9508 plays a beneficial role in protecting type II Collagen and aggrecan from degeneration by attenuating the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5.	GW9508	15-21	ADAM metallopeptidase with thrombospondin type 1 motif 5	Homo sapiens	170-178
32606604-12	2020	Additionally, GW9508 reduces the appearance of pro-inflammatory cytokines and suppresses NF-kappaB activation in AGEs-induced chondrocytes.	GW9508	14-20	nuclear factor kappa B subunit 1	Homo sapiens	89-98
32606604-13	2020	Notably, co-treatment with GW1100, a specific antagonist of GPR40, abolishes the beneficial role of GW9508 against AGEs, implying that GPR40 mediates these effects of GW9508.	GW9508	100-106	free fatty acid receptor 1	Homo sapiens	60-65
32606604-13	2020	Notably, co-treatment with GW1100, a specific antagonist of GPR40, abolishes the beneficial role of GW9508 against AGEs, implying that GPR40 mediates these effects of GW9508.	GW9508	167-173	free fatty acid receptor 1	Homo sapiens	60-65
32606604-13	2020	Notably, co-treatment with GW1100, a specific antagonist of GPR40, abolishes the beneficial role of GW9508 against AGEs, implying that GPR40 mediates these effects of GW9508.	GW9508	167-173	free fatty acid receptor 1	Homo sapiens	135-140
32606604-14	2020	Conclusion: Our results suggest that GPR40 is a novel therapeutic target for OA and that GPR40 agonists, including GW9508, may have therapeutic potential in preventing and slowing the progression of OA.	GW9508	115-121	free fatty acid receptor 1	Homo sapiens	89-94
32431615-8	2020	Besides, HaCaT cells stimulated with LA or GW9508 increased the activity of MMP-9 and the expression of IL-8.	GW9508	43-49	C-X-C motif chemokine ligand 8	Homo sapiens	104-108
32431615-12	2020	Furthermore, IL-8 secreted by HaCaT cells stimulated with LA or GW9508, contributed to neutrophil chemotaxis.	GW9508	64-70	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
31809762-0	2020	GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer"s disease.	GW9508	0-6	cAMP responsive element binding protein 1	Mus musculus	53-57
31809762-0	2020	GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer"s disease.	GW9508	0-6	mitogen-activated protein kinase 8	Mus musculus	62-65
31809762-3	2020	GPR40 agonist GW9508 and antagonist GW1100 were respectively given by i.c.v.	GW9508	14-20	free fatty acid receptor 1	Mus musculus	0-5
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	amyloid beta (A4) precursor protein	Mus musculus	101-108
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	cAMP responsive element binding protein 1	Mus musculus	159-163
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	mitogen-activated protein kinase 8	Mus musculus	332-335
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	mitogen-activated protein kinase 8	Mus musculus	337-340
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	interleukin 6	Mus musculus	380-384
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	interleukin 1 beta	Mus musculus	386-394
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	tumor necrosis factor	Mus musculus	396-405
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	caspase 3	Mus musculus	410-419
31214048-6	2019	In endothelin 1-precontracted porcine LES strips, the FFA1 selective agonists, fasiglifam, TUG424, and GW9508, caused marked relaxations in a concentration-dependent manner.	GW9508	103-109	endothelin 1	Homo sapiens	3-15
31870843-5	2020	In the present study, we tested the effects of two GPR120 agonists-GW9508 and TUG-891-in mitigating endothelial insult induced by ox-LDL in human aortic endothelial cells (HAECs).	GW9508	67-73	free fatty acid receptor 4	Homo sapiens	51-57
31498851-0	2019	G-protein-coupled receptor 40 agonist GW9508 potentiates glucose-stimulated insulin secretion through activation of protein kinase Calpha and epsilon in INS-1 cells.	GW9508	38-44	free fatty acid receptor 1	Rattus norvegicus	0-29
31498851-2	2019	We examined whether a GPR40 agonist, GW9508, could stimulate conventional and novel isoforms of PKC at two glucose concentrations (3 mM and 20 mM) in INS-1D cells.	GW9508	37-43	free fatty acid receptor 1	Rattus norvegicus	22-27
31498851-2	2019	We examined whether a GPR40 agonist, GW9508, could stimulate conventional and novel isoforms of PKC at two glucose concentrations (3 mM and 20 mM) in INS-1D cells.	GW9508	37-43	protein kinase C, alpha	Rattus norvegicus	96-99
31498851-6	2019	RESULTS: At 3 mM glucose, GW9508 induced sustained MARCKS-GFP translocation to the cytosol, irrespective of changes in [Ca2+]i.	GW9508	26-32	myristoylated alanine rich protein kinase C substrate	Rattus norvegicus	51-57
31498851-7	2019	At 20 mM glucose, GW9508 induced sustained MARCKS-GFP translocation but also transient translocation that followed sharp increases in [Ca2+]i.	GW9508	18-24	myristoylated alanine rich protein kinase C substrate	Rattus norvegicus	43-49
31498851-9	2019	At 20 mM glucose, GW9508 induced transient translocation of PKCalpha and sustained translocation as well as transient translocation of PKCepsilon.	GW9508	18-24	protein kinase C, alpha	Rattus norvegicus	60-68
31498851-10	2019	While the inhibitors (75 muM) of each PKC isotype reduced GW9508-potentiated, glucose-stimulated insulin secretion in INS-1D cells, the PKCepsilon inhibitor had a more potent effect.	GW9508	58-64	protein kinase C, alpha	Rattus norvegicus	38-41
31129422-4	2019	This study was aimed to investigate the effect of GPR40 stimulation on proinflammatory cytokine (TNFalpha and IL-1beta)-induced tight junction disruption in human airway epithelial Calu-3 cells using GW9508, a GPR40 agonist.	GW9508	200-206	free fatty acid receptor 1	Homo sapiens	50-55
31129422-4	2019	This study was aimed to investigate the effect of GPR40 stimulation on proinflammatory cytokine (TNFalpha and IL-1beta)-induced tight junction disruption in human airway epithelial Calu-3 cells using GW9508, a GPR40 agonist.	GW9508	200-206	tumor necrosis factor	Homo sapiens	97-105
31129422-5	2019	We found that stimulation of GPR40 by GW9508 attenuated the cytokine-induced airway epithelial barrier leakage as analyzed by measurements of transepithelial electrical resistance and transepithelial flux of fluorescently labeled dextran (molecular weight of 4 kDa).	GW9508	38-44	free fatty acid receptor 1	Homo sapiens	29-34
31129422-6	2019	Furthermore, GW9508 prevented the cytokine-induced dislocalization of zonula occludens (ZO)-1, occludin and claudin-1.	GW9508	13-19	tight junction protein 1	Homo sapiens	70-93
31129422-6	2019	Furthermore, GW9508 prevented the cytokine-induced dislocalization of zonula occludens (ZO)-1, occludin and claudin-1.	GW9508	13-19	occludin	Homo sapiens	95-103
31129422-6	2019	Furthermore, GW9508 prevented the cytokine-induced dislocalization of zonula occludens (ZO)-1, occludin and claudin-1.	GW9508	13-19	claudin 1	Homo sapiens	108-117
31129422-7	2019	The barrier-protective effect of GW9508 was abolished by a GPR40 antagonist, but not a GPR120 antagonist.	GW9508	33-39	free fatty acid receptor 1	Homo sapiens	59-64
31129422-9	2019	Intriguingly, GW9508 inhibited cytokine-induced airway epithelial barrier disruption through suppression of extracellular signal-regulated kinase (ERK) phosphorylation in a phospholipase C (PLC) and calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta)-dependent manner.	GW9508	14-20	mitogen-activated protein kinase 1	Homo sapiens	108-145
31129422-9	2019	Intriguingly, GW9508 inhibited cytokine-induced airway epithelial barrier disruption through suppression of extracellular signal-regulated kinase (ERK) phosphorylation in a phospholipase C (PLC) and calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta)-dependent manner.	GW9508	14-20	mitogen-activated protein kinase 1	Homo sapiens	147-150
31129422-9	2019	Intriguingly, GW9508 inhibited cytokine-induced airway epithelial barrier disruption through suppression of extracellular signal-regulated kinase (ERK) phosphorylation in a phospholipase C (PLC) and calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta)-dependent manner.	GW9508	14-20	calcium/calmodulin dependent protein kinase kinase 1	Homo sapiens	256-265
31129318-0	2019	Anti-atherosclerotic action of GW9508 - Free fatty acid receptors activator - In apoE-knockout mice.	GW9508	31-37	apolipoprotein E	Mus musculus	81-85
31129318-3	2019	METHODS: The present study investigates the influence of prolonged treatment with GW9508 - agonist of FFAR1 and FFAR4 - on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods.	GW9508	82-88	free fatty acid receptor 1	Mus musculus	102-107
31129318-3	2019	METHODS: The present study investigates the influence of prolonged treatment with GW9508 - agonist of FFAR1 and FFAR4 - on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods.	GW9508	82-88	free fatty acid receptor 4	Mus musculus	112-117
31129318-3	2019	METHODS: The present study investigates the influence of prolonged treatment with GW9508 - agonist of FFAR1 and FFAR4 - on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods.	GW9508	82-88	apolipoprotein E	Mus musculus	168-172
31129318-4	2019	RESULTS: GW9508 administration has led to the reduction of atheroscletoric plaque size in an apoE-knockout mice model.	GW9508	9-15	apolipoprotein E	Mus musculus	93-97
31129318-6	2019	CONCLUSIONS: Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis.	GW9508	41-47	free fatty acid receptor 1	Mus musculus	234-239
31129318-6	2019	CONCLUSIONS: Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis.	GW9508	41-47	free fatty acid receptor 4	Mus musculus	240-245
31295865-5	2019	In vitro, pretreatment of rat proximal tubular (NRK52E) cells with GW9508, a GPR40 agonist, attenuated the decreased cell viability, increased the Bax/Bcl-2 protein expression ratio, increased protein expression of cleaved caspase-3 and activated the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit induced by TNF-alpha treatment.	GW9508	67-73	free fatty acid receptor 1	Rattus norvegicus	77-82
31295865-5	2019	In vitro, pretreatment of rat proximal tubular (NRK52E) cells with GW9508, a GPR40 agonist, attenuated the decreased cell viability, increased the Bax/Bcl-2 protein expression ratio, increased protein expression of cleaved caspase-3 and activated the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit induced by TNF-alpha treatment.	GW9508	67-73	BCL2 associated X, apoptosis regulator	Rattus norvegicus	147-150
31295865-5	2019	In vitro, pretreatment of rat proximal tubular (NRK52E) cells with GW9508, a GPR40 agonist, attenuated the decreased cell viability, increased the Bax/Bcl-2 protein expression ratio, increased protein expression of cleaved caspase-3 and activated the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit induced by TNF-alpha treatment.	GW9508	67-73	BCL2, apoptosis regulator	Rattus norvegicus	151-156
31295865-5	2019	In vitro, pretreatment of rat proximal tubular (NRK52E) cells with GW9508, a GPR40 agonist, attenuated the decreased cell viability, increased the Bax/Bcl-2 protein expression ratio, increased protein expression of cleaved caspase-3 and activated the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit induced by TNF-alpha treatment.	GW9508	67-73	caspase 3	Rattus norvegicus	223-232
31295865-5	2019	In vitro, pretreatment of rat proximal tubular (NRK52E) cells with GW9508, a GPR40 agonist, attenuated the decreased cell viability, increased the Bax/Bcl-2 protein expression ratio, increased protein expression of cleaved caspase-3 and activated the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit induced by TNF-alpha treatment.	GW9508	67-73	synaptotagmin 1	Rattus norvegicus	310-313
31295865-5	2019	In vitro, pretreatment of rat proximal tubular (NRK52E) cells with GW9508, a GPR40 agonist, attenuated the decreased cell viability, increased the Bax/Bcl-2 protein expression ratio, increased protein expression of cleaved caspase-3 and activated the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 subunit induced by TNF-alpha treatment.	GW9508	67-73	tumor necrosis factor	Rattus norvegicus	333-342
31214048-6	2019	In endothelin 1-precontracted porcine LES strips, the FFA1 selective agonists, fasiglifam, TUG424, and GW9508, caused marked relaxations in a concentration-dependent manner.	GW9508	103-109	free fatty acid receptor 1	Homo sapiens	54-58
30981281-10	2019	GW9508 also markedly stimulated gene and protein expression of IL-10 and beta-endorphin in cultured primary spinal microglia and astrocytes but not in neurons, originated from 1-day-old neonatal rats.	GW9508	0-6	interleukin 10	Rattus norvegicus	63-68
29777569-2	2018	The FFA1 agonist GW9508 has great potential for the treatment of type 2 diabetes mellitus, but it has been suffering from high plasma clearance probably because the phenylpropanoic acid is vulnerable to beta-oxidation.	GW9508	17-23	free fatty acid receptor 1	Mus musculus	4-8
30981281-7	2019	Intrathecal injection of the GPR40 agonist GW9508 dose-dependently attenuated mechanical allodynia and thermal hyperalgesia in neuropathic rats, with Emax values of 80% and 100% MPE and ED50 values of 6.7 and 5.4 mug, respectively.	GW9508	43-49	free fatty acid receptor 1	Rattus norvegicus	29-34
30981281-9	2019	Intrathecal GW9508 significantly enhanced IL-10 and beta-endorphin immunostaining in spinal microglia and astrocytes but not in neurons.	GW9508	12-18	interleukin 10	Rattus norvegicus	42-47
30981281-11	2019	The IL-10 antibody inhibited GW9508-stimulated gene expression of the beta-endorphin precursor proopiomelanocortin (POMC) but not IL-10, whereas the beta-endorphin antibody did not affect GW9508-stimulated IL-10 or POMC gene expression.	GW9508	29-35	interleukin 10	Rattus norvegicus	4-9
30981281-11	2019	The IL-10 antibody inhibited GW9508-stimulated gene expression of the beta-endorphin precursor proopiomelanocortin (POMC) but not IL-10, whereas the beta-endorphin antibody did not affect GW9508-stimulated IL-10 or POMC gene expression.	GW9508	29-35	proopiomelanocortin	Rattus norvegicus	116-120
30981281-11	2019	The IL-10 antibody inhibited GW9508-stimulated gene expression of the beta-endorphin precursor proopiomelanocortin (POMC) but not IL-10, whereas the beta-endorphin antibody did not affect GW9508-stimulated IL-10 or POMC gene expression.	GW9508	29-35	proopiomelanocortin	Rattus norvegicus	215-219
30981281-11	2019	The IL-10 antibody inhibited GW9508-stimulated gene expression of the beta-endorphin precursor proopiomelanocortin (POMC) but not IL-10, whereas the beta-endorphin antibody did not affect GW9508-stimulated IL-10 or POMC gene expression.	GW9508	188-194	interleukin 10	Rattus norvegicus	4-9
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	mitogen activated protein kinase 14	Rattus norvegicus	88-91
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	Eph receptor B1	Rattus norvegicus	93-130
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	Eph receptor B1	Rattus norvegicus	132-135
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	mitogen-activated protein kinase 8	Rattus norvegicus	142-165
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	mitogen-activated protein kinase 8	Rattus norvegicus	167-170
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	interleukin 10	Rattus norvegicus	204-209
30981281-12	2019	GW9508 increased phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and its stimulatory effects on IL-10 and POMC expression were blocked by each MAPK isoform inhibitor.	GW9508	0-6	proopiomelanocortin	Rattus norvegicus	214-218
30981281-13	2019	Spinal GW9508-induced mechanical antiallodynia was completely blocked by intrathecal minocycline, IL-10 neutralizing antibody, beta-endorphin antiserum, and mu-opioid receptor-preferred antagonist naloxone.	GW9508	7-13	interleukin 10	Rattus norvegicus	98-103
29981843-5	2018	Next, we demonstrated that chronic treatment with docosahexaenoic acid (DHA) or the synthetic GPR40 agonist, GW9508, significantly alleviates cognitive functions in mice, which correlates with increased BDNF expression in the hippocampus.	GW9508	109-115	free fatty acid receptor 1	Mus musculus	94-99
29981843-5	2018	Next, we demonstrated that chronic treatment with docosahexaenoic acid (DHA) or the synthetic GPR40 agonist, GW9508, significantly alleviates cognitive functions in mice, which correlates with increased BDNF expression in the hippocampus.	GW9508	109-115	brain derived neurotrophic factor	Mus musculus	203-207
29321392-3	2018	We have already demonstrated that the intracerebroventricular administration of DHA or GW9508, a GPR40/FFAR1 agonist, suppresses formalin-induced pain behavior.	GW9508	87-93	free fatty acid receptor 1	Homo sapiens	97-102
29750897-6	2018	The cell motile activities of DLD-5FU and DLD-CDDP cells were reduced by GW9508 which is an agonist of FFA1 and FFA4.	GW9508	73-79	free fatty acid receptor 1	Homo sapiens	103-107
29777058-3	2018	14,15-EET, 11,12-EET, arachidonic acid, and the GPR40 agonist GW9508 increase intracellular calcium concentrations in human GPR40-overexpressing HEK293 cells (EC50 = 0.58 +- 0.08 mum, 0.91 +- 0.08 mum, 3.9 +- 0.06 mum, and 19 +- 0.37 nm, respectively).	GW9508	62-68	free fatty acid receptor 1	Homo sapiens	48-53
29777058-3	2018	14,15-EET, 11,12-EET, arachidonic acid, and the GPR40 agonist GW9508 increase intracellular calcium concentrations in human GPR40-overexpressing HEK293 cells (EC50 = 0.58 +- 0.08 mum, 0.91 +- 0.08 mum, 3.9 +- 0.06 mum, and 19 +- 0.37 nm, respectively).	GW9508	62-68	free fatty acid receptor 1	Homo sapiens	124-129
29777058-6	2018	The GPR40 antagonist GW1100 and siRNA-mediated GPR40 silencing blocked the EET- and GW9508-induced calcium increases.	GW9508	84-90	free fatty acid receptor 1	Homo sapiens	4-9
29777058-6	2018	The GPR40 antagonist GW1100 and siRNA-mediated GPR40 silencing blocked the EET- and GW9508-induced calcium increases.	GW9508	84-90	free fatty acid receptor 1	Homo sapiens	47-52
29321392-3	2018	We have already demonstrated that the intracerebroventricular administration of DHA or GW9508, a GPR40/FFAR1 agonist, suppresses formalin-induced pain behavior.	GW9508	87-93	free fatty acid receptor 1	Homo sapiens	103-108
29568424-2	2017	Herein, we describe the design and synthesis of FAAzo-10, a light-controllable GPR40 agonist based on Gw-9508.	GW9508	102-109	free fatty acid receptor 1	Mus musculus	79-84
29913106-3	2018	This study aimed to investigate the function of GPR40 in regulating tight junction assembly in human airway epithelial cells (Calu-3 cells) using GW9508, a GPR40 agonist.	GW9508	146-152	free fatty acid receptor 1	Homo sapiens	48-53
29913106-3	2018	This study aimed to investigate the function of GPR40 in regulating tight junction assembly in human airway epithelial cells (Calu-3 cells) using GW9508, a GPR40 agonist.	GW9508	146-152	free fatty acid receptor 1	Homo sapiens	156-161
29913106-5	2018	Intracellular Ca2+ measurements confirmed that GW9508 stimulated GPR40, but not GPR120.	GW9508	47-53	free fatty acid receptor 1	Homo sapiens	65-70
29913106-10	2018	Our results indicate that GPR40 stimulation by GW9508 leads to AMPK activation via calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta).	GW9508	47-53	free fatty acid receptor 1	Homo sapiens	26-31
29913106-10	2018	Our results indicate that GPR40 stimulation by GW9508 leads to AMPK activation via calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta).	GW9508	47-53	calcium/calmodulin dependent protein kinase kinase 2	Homo sapiens	140-149
28159555-6	2017	The cell motile activity of MG63-R7 cells was stimulated by GW9508, which is an agonist of GPR120 and GPR40.	GW9508	60-66	free fatty acid receptor 4	Homo sapiens	91-97
28446241-11	2017	Reducing GPR120 hypothalamic expression using a lentivirus-based approach resulted in the loss of the anti-inflammatory effect of GW9508 and increased energy efficiency.	GW9508	130-136	free fatty acid receptor 4	Mus musculus	9-15
28446241-12	2017	Intracerebroventricular treatment with the GPR120- and GPR40-specific agonists TUG1197 and TUG905, respectively, resulted in milder effects than those produced by GW9508.	GW9508	163-169	free fatty acid receptor 4	Mus musculus	43-49
28446241-12	2017	Intracerebroventricular treatment with the GPR120- and GPR40-specific agonists TUG1197 and TUG905, respectively, resulted in milder effects than those produced by GW9508.	GW9508	163-169	free fatty acid receptor 1	Mus musculus	55-60
28731171-6	2017	In addition, PTF enhanced the protein expression of GPR40 and to a certain extent strengthened the protein expression of PKC, increased cellular levels of triphosphoinositide (IP3) and diacylglycerol (DAG), and promoted GW9508-stimulated activity of PLC and PKC reduced by PA in INS-1 cells, which were blocked by PLC inhibitor U-73122 and PKC inhibitor staurosporine, respectively.	GW9508	220-226	free fatty acid receptor 1	Rattus norvegicus	52-57
28159555-6	2017	The cell motile activity of MG63-R7 cells was stimulated by GW9508, which is an agonist of GPR120 and GPR40.	GW9508	60-66	free fatty acid receptor 1	Homo sapiens	102-107
28159555-7	2017	Moreover, a GPR40 antagonist GW1100 elevated the cell motile activity of MG63-R7 cells in the presence of GW9508.	GW9508	106-112	free fatty acid receptor 1	Homo sapiens	12-17
28154332-7	2017	Furthermore, the intracerebroventricular injection of DHA or GW9508, which is a selective GPR40/FFA1 agonist, attenuates formalin-induced inflammatory pain behavior through increasing beta-endorphin release in the hypothalamus.	GW9508	61-67	free fatty acid receptor 1	Homo sapiens	90-95
27611773-1	2017	SCOPE: The stimulation of the free fatty acid receptor G-protein coupled receptor (GPR) 40 by GW9508 prevents bone loss by inhibiting osteoclast activity, both in vitro and in vivo.	GW9508	94-100	G protein-coupled receptor 34	Mus musculus	55-81
27611773-1	2017	SCOPE: The stimulation of the free fatty acid receptor G-protein coupled receptor (GPR) 40 by GW9508 prevents bone loss by inhibiting osteoclast activity, both in vitro and in vivo.	GW9508	94-100	G protein-coupled receptor 34	Mus musculus	83-86
28154332-7	2017	Furthermore, the intracerebroventricular injection of DHA or GW9508, which is a selective GPR40/FFA1 agonist, attenuates formalin-induced inflammatory pain behavior through increasing beta-endorphin release in the hypothalamus.	GW9508	61-67	proopiomelanocortin	Homo sapiens	184-198
26331585-9	2016	In addition, GW9508 which is an agonist of GPR40 and GPR120 suppressed the cell motile and invasive activities of HT1080 cells treated with CDDP as well as the MMP activation.	GW9508	13-19	free fatty acid receptor 1	Homo sapiens	43-48
26331585-9	2016	In addition, GW9508 which is an agonist of GPR40 and GPR120 suppressed the cell motile and invasive activities of HT1080 cells treated with CDDP as well as the MMP activation.	GW9508	13-19	free fatty acid receptor 4	Homo sapiens	53-59
26331585-9	2016	In addition, GW9508 which is an agonist of GPR40 and GPR120 suppressed the cell motile and invasive activities of HT1080 cells treated with CDDP as well as the MMP activation.	GW9508	13-19	matrix metallopeptidase 2	Homo sapiens	160-163
27764222-7	2016	Moreover, GW9508, a specific ligand for G-protein coupled receptor (Gpr)-120/Free fatty acid receptor (Ffar)-4, mimicked the effects of EPA.	GW9508	10-16	G protein-coupled receptor 34	Mus musculus	40-66
27489163-7	2016	Treatment of Ffar4 agonist (GW9508) recapitulated the thermogenic activation of EPA by increasing oxygen consumption rate, brown-specific marker genes, and miR-30b and 378, which were abrogated in Ffar4-silenced cells.	GW9508	28-34	free fatty acid receptor 4	Mus musculus	13-18
27489163-7	2016	Treatment of Ffar4 agonist (GW9508) recapitulated the thermogenic activation of EPA by increasing oxygen consumption rate, brown-specific marker genes, and miR-30b and 378, which were abrogated in Ffar4-silenced cells.	GW9508	28-34	microRNA 30b	Mus musculus	156-163
27489163-7	2016	Treatment of Ffar4 agonist (GW9508) recapitulated the thermogenic activation of EPA by increasing oxygen consumption rate, brown-specific marker genes, and miR-30b and 378, which were abrogated in Ffar4-silenced cells.	GW9508	28-34	free fatty acid receptor 4	Mus musculus	197-202
26869446-4	2016	The Cx HC activity of these cells increased after 5 min of treatment with LA or GW9508, an agonist of GPR40/GPR120; or exposure to extracellular divalent cation-free solution (DCFS), known to increase the open probability of Cx HCs, yields an immediate increase in Cx HC activity of similar intensity and additive with LA-induced change.	GW9508	80-86	free fatty acid receptor 1	Homo sapiens	102-107
27363707-4	2016	Our results showed that natural (oleic and linoleic acid) and synthetic (GW9508) FFAR1/GPR40 agonists increased ERK1/2, p38 MAPK and Akt phosphorylation, and that the FFAR1/GPR40 antagonist GW1100 reduced these responses.	GW9508	73-79	free fatty acid receptor 1	Bos taurus	81-86
27363707-4	2016	Our results showed that natural (oleic and linoleic acid) and synthetic (GW9508) FFAR1/GPR40 agonists increased ERK1/2, p38 MAPK and Akt phosphorylation, and that the FFAR1/GPR40 antagonist GW1100 reduced these responses.	GW9508	73-79	mitogen-activated protein kinase 3	Bos taurus	112-118
27363707-4	2016	Our results showed that natural (oleic and linoleic acid) and synthetic (GW9508) FFAR1/GPR40 agonists increased ERK1/2, p38 MAPK and Akt phosphorylation, and that the FFAR1/GPR40 antagonist GW1100 reduced these responses.	GW9508	73-79	free fatty acid receptor 1	Bos taurus	167-172
26869446-4	2016	The Cx HC activity of these cells increased after 5 min of treatment with LA or GW9508, an agonist of GPR40/GPR120; or exposure to extracellular divalent cation-free solution (DCFS), known to increase the open probability of Cx HCs, yields an immediate increase in Cx HC activity of similar intensity and additive with LA-induced change.	GW9508	80-86	free fatty acid receptor 4	Homo sapiens	108-114
27121981-4	2016	In the present study, we found that activation of GPR40 by its agonist GW9508 attenuated Liver X receptor (LXR)-induced hepatic lipid accumulation.	GW9508	71-77	free fatty acid receptor 1	Homo sapiens	50-55
26976092-9	2016	All GPR40 receptor agonist GW9508, treatment groups enhanced the learning and memory ability in Step-through passive test, Morris water maze test, Hole board discrimination test, Novel object recognition test.	GW9508	27-33	free fatty acid receptor 1	Mus musculus	4-9
27121981-4	2016	In the present study, we found that activation of GPR40 by its agonist GW9508 attenuated Liver X receptor (LXR)-induced hepatic lipid accumulation.	GW9508	71-77	nuclear receptor subfamily 1, group H, member 3	Mus musculus	107-110
27121981-6	2016	All these effects of LXR were dramatically downregulated after GW9508 supplementation.	GW9508	63-69	nuclear receptor subfamily 1, group H, member 3	Mus musculus	21-24
27121981-8	2016	Taken together, our results demonstrated that GW9508 exerts a beneficial effect to ameliorate LXR-induced hepatic steatosis through regulation of AMPK signaling pathway.	GW9508	46-52	nuclear receptor subfamily 1, group H, member 3	Mus musculus	94-97
26853521-1	2016	Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study.	GW9508	94-100	chromogranin A	Mus musculus	156-159
26853521-1	2016	Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study.	GW9508	94-100	luteinizing hormone beta	Mus musculus	161-164
26853521-1	2016	Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study.	GW9508	94-100	follicle stimulating hormone beta	Mus musculus	169-173
26853521-1	2016	Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study.	GW9508	94-100	free fatty acid receptor 4	Mus musculus	196-202
26791484-5	2016	In Caco-2 cells, GPR120 was internalized, bound to beta-arrestin-2, and attenuated NF-kappaB activation in response to 30-min exposure to the agonists GW9508, TUG-891, or docosahexaenoic acid.	GW9508	151-157	free fatty acid receptor 4	Homo sapiens	17-23
26342087-6	2015	The long-chain free fatty acids (oleic acid and linoleic acid) and GW9508 (FFAR1/FFAR4 dual agonist) dose-dependently stimulated transient intracellular Ca(2+) concentration ([Ca(2+)]i) increases and inositol phosphate synthesis in HASM cells.	GW9508	67-73	free fatty acid receptor 1	Homo sapiens	75-80
26280807-4	2016	Activation of GPR120 by its ligand GW9508 suppressed receptor activator of NF- kappaB ligand (RANKL)-induced osteoclast differentiation and the expression of nuclear factor of activated T cells c1 (NFATc1), a key modulator of osteoclastogenesis.	GW9508	35-41	free fatty acid receptor 4	Homo sapiens	14-20
26280807-4	2016	Activation of GPR120 by its ligand GW9508 suppressed receptor activator of NF- kappaB ligand (RANKL)-induced osteoclast differentiation and the expression of nuclear factor of activated T cells c1 (NFATc1), a key modulator of osteoclastogenesis.	GW9508	35-41	TNF superfamily member 11	Homo sapiens	94-99
26280807-4	2016	Activation of GPR120 by its ligand GW9508 suppressed receptor activator of NF- kappaB ligand (RANKL)-induced osteoclast differentiation and the expression of nuclear factor of activated T cells c1 (NFATc1), a key modulator of osteoclastogenesis.	GW9508	35-41	nuclear factor of activated T cells 1	Homo sapiens	198-204
26821052-8	2016	Two synthetic FFAR agonists, GW9508 and TUG-891, likewise inhibited LPA- and EGF-induced proliferation.	GW9508	29-35	epidermal growth factor	Homo sapiens	77-80
26699911-4	2016	To further investigate this hypothesis, biological effects of GW9508, a synthetic agonist for GPR40, was first tested on osteoblast differentiation parameters.	GW9508	62-68	free fatty acid receptor 1	Mus musculus	94-99
26699911-10	2016	Nevertheless, a significant increase in OPG expression was observed upon GW9508 treatment that contribute to explain the GPR40-related osteoporosis prevention.	GW9508	73-79	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	40-43
26699911-10	2016	Nevertheless, a significant increase in OPG expression was observed upon GW9508 treatment that contribute to explain the GPR40-related osteoporosis prevention.	GW9508	73-79	free fatty acid receptor 1	Mus musculus	121-126
26342087-6	2015	The long-chain free fatty acids (oleic acid and linoleic acid) and GW9508 (FFAR1/FFAR4 dual agonist) dose-dependently stimulated transient intracellular Ca(2+) concentration ([Ca(2+)]i) increases and inositol phosphate synthesis in HASM cells.	GW9508	67-73	free fatty acid receptor 4	Homo sapiens	81-86
26134561-7	2015	DHA and GW9508, a GPR120 agonist, increased GPR120 expression.	GW9508	8-14	free fatty acid receptor 4	Homo sapiens	18-24
26071852-1	2015	Previous studies have shown that the administration of docosahexaenoic acid (DHA) or GW9508, a GPR40/FFA1 (free fatty acid receptor) agonist, facilitates beta-endorphin release in the arcuate nucleus of the hypothalamus in mice.	GW9508	85-91	free fatty acid receptor 1	Mus musculus	95-100
26071852-4	2015	The intracerebroventricular injection of DHA or GW9508 significantly increased PC2 protein expression in the hypothalamus.	GW9508	48-54	proprotein convertase subtilisin/kexin type 2	Mus musculus	79-82
26134561-7	2015	DHA and GW9508, a GPR120 agonist, increased GPR120 expression.	GW9508	8-14	free fatty acid receptor 4	Homo sapiens	44-50
25790291-5	2015	Stimulation with a synthetic GPR120 agonist, GW9508, induced rapid down-regulation of cell surface expression of GPR120, suggesting ligand-dependent receptor internalization.	GW9508	45-51	free fatty acid receptor 4	Homo sapiens	29-35
25790291-5	2015	Stimulation with a synthetic GPR120 agonist, GW9508, induced rapid down-regulation of cell surface expression of GPR120, suggesting ligand-dependent receptor internalization.	GW9508	45-51	free fatty acid receptor 4	Homo sapiens	113-119
25576830-7	2015	Furthermore, in vivo GW9508 administration rescued estrogen-deficient bone loss, indicating the essential role of the GPR40 receptor.	GW9508	21-27	free fatty acid receptor 1	Mus musculus	118-123
25281202-10	2014	BCAO-induced mechanical hyperalgesia was significantly decreased by intracerebroventricular injection of docosahexaenoic acid or GW9508, a GPR40 agonist; furthermore, these effects were reversed by GW1100, a GPR40 antagonist.	GW9508	129-135	free fatty acid receptor 1	Mus musculus	139-144
25447053-8	2015	Dual agonists of GPR40 and GPR120, GW9508 and linoleic acid, respectively, increased GLP-2 production from L cells, but these agonists decreased it in the presence of TNF-alpha.	GW9508	35-41	glucagon	Homo sapiens	85-90
25447053-8	2015	Dual agonists of GPR40 and GPR120, GW9508 and linoleic acid, respectively, increased GLP-2 production from L cells, but these agonists decreased it in the presence of TNF-alpha.	GW9508	35-41	tumor necrosis factor	Homo sapiens	167-176
25447053-9	2015	The GPR40 antagonist, GW1100, inhibited the GW9508-induced increase in GLP-2 production, and silencing GPR120 resulted in further elevation of GLP-2 production.	GW9508	44-50	free fatty acid receptor 1	Homo sapiens	4-9
25447053-9	2015	The GPR40 antagonist, GW1100, inhibited the GW9508-induced increase in GLP-2 production, and silencing GPR120 resulted in further elevation of GLP-2 production.	GW9508	44-50	glucagon	Homo sapiens	71-76
25889021-3	2015	RESULTS: Intrathecal injection of GPR40 agonist (MEDICA16 or GW9508) dose-dependently reduced ipsilateral mechanical allodynia in CFA and SNL models and thermal hyperalgesia in carrageenan model.	GW9508	61-67	free fatty acid receptor 1	Mus musculus	34-39
25281202-10	2014	BCAO-induced mechanical hyperalgesia was significantly decreased by intracerebroventricular injection of docosahexaenoic acid or GW9508, a GPR40 agonist; furthermore, these effects were reversed by GW1100, a GPR40 antagonist.	GW9508	129-135	free fatty acid receptor 1	Mus musculus	208-213
25092426-12	2014	The cisplatin-induced generation of reactive oxygen species (ROS) and the activation of the Src/epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway were also counteracted by pre-treatment with GW9508.	GW9508	233-239	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	92-95
25092426-12	2014	The cisplatin-induced generation of reactive oxygen species (ROS) and the activation of the Src/epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway were also counteracted by pre-treatment with GW9508.	GW9508	233-239	epidermal growth factor receptor	Homo sapiens	96-128
25092426-12	2014	The cisplatin-induced generation of reactive oxygen species (ROS) and the activation of the Src/epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway were also counteracted by pre-treatment with GW9508.	GW9508	233-239	epidermal growth factor receptor	Homo sapiens	130-134
25008074-3	2014	In this study, a high fat diet (HFD)-induced hepatic steatosis animal model was utilized to evaluate the effects of an FFAR1 agonist, GW9508, on hepatic lipid accumulation, and HepG2 hepatoma cells were also used to clarify the possible mechanisms.	GW9508	134-140	free fatty acid receptor 1	Homo sapiens	119-124
25008074-5	2014	Knockdown of hepatic Ffar1 by lentiviral vectors containing short hairpin RNA targeted to Ffar1 diminished the effect of GW9508 in HFD mice.	GW9508	121-127	free fatty acid receptor 1	Mus musculus	21-26
25008074-5	2014	Knockdown of hepatic Ffar1 by lentiviral vectors containing short hairpin RNA targeted to Ffar1 diminished the effect of GW9508 in HFD mice.	GW9508	121-127	free fatty acid receptor 1	Mus musculus	90-95
25008074-7	2014	Moreover, GW9508 downregulated the expression of sterol regulatory element-binding protein 1 (SREBP1) through a p38-dependent pathway, whereas knockdown of Ffar1 in HepG2 cells diminished the effect of GW9508 on the decrease in SREBP1.	GW9508	10-16	sterol regulatory element binding transcription factor 1	Homo sapiens	49-92
25008074-7	2014	Moreover, GW9508 downregulated the expression of sterol regulatory element-binding protein 1 (SREBP1) through a p38-dependent pathway, whereas knockdown of Ffar1 in HepG2 cells diminished the effect of GW9508 on the decrease in SREBP1.	GW9508	10-16	sterol regulatory element binding transcription factor 1	Homo sapiens	94-100
25008074-7	2014	Moreover, GW9508 downregulated the expression of sterol regulatory element-binding protein 1 (SREBP1) through a p38-dependent pathway, whereas knockdown of Ffar1 in HepG2 cells diminished the effect of GW9508 on the decrease in SREBP1.	GW9508	10-16	mitogen-activated protein kinase 14	Homo sapiens	112-115
25008074-7	2014	Moreover, GW9508 downregulated the expression of sterol regulatory element-binding protein 1 (SREBP1) through a p38-dependent pathway, whereas knockdown of Ffar1 in HepG2 cells diminished the effect of GW9508 on the decrease in SREBP1.	GW9508	10-16	sterol regulatory element binding transcription factor 1	Homo sapiens	228-234
25008074-7	2014	Moreover, GW9508 downregulated the expression of sterol regulatory element-binding protein 1 (SREBP1) through a p38-dependent pathway, whereas knockdown of Ffar1 in HepG2 cells diminished the effect of GW9508 on the decrease in SREBP1.	GW9508	202-208	free fatty acid receptor 1	Homo sapiens	156-161
25008074-8	2014	Considering all these results together, GW9508 exerts a therapeutic effect to improve hepatic steatosis through a p38-dependent pathway.	GW9508	40-46	mitogen-activated protein kinase 14	Homo sapiens	114-117
24734983-7	2014	The results showed that DHA, PD98059 (an ERK1/2 inhibitor), and GW9508 (a GPR120 agonist) inhibited VEGF-induced cell migration.	GW9508	64-70	free fatty acid receptor 4	Homo sapiens	74-80
24673159-4	2014	DHA and GW9508 activate cPLA2 via GPR120 receptor, G protein Galphaq and scaffold protein beta-arrestin 2.	GW9508	8-14	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	24-29
24673159-4	2014	DHA and GW9508 activate cPLA2 via GPR120 receptor, G protein Galphaq and scaffold protein beta-arrestin 2.	GW9508	8-14	free fatty acid receptor 4	Mus musculus	34-40
24673159-5	2014	Extracellular signal-regulated kinase 1/2 activation is involved in DHA- and GW9508-induced cPLA2 activation, but not p38 mitogen-activated protein kinase.	GW9508	77-83	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	92-97
24673159-6	2014	The anti-inflammatory role of DHA and GW9508 is in part via activation of cPLA2 , COX-2 and production of PGE2 as a cPLA2 inhibitor or a COX-2 inhibitor partially reverses the DHA- and GW9508-induced inhibition of lipopolysaccharide-induced interleukin-6 secretion.	GW9508	38-44	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	74-79
24673159-6	2014	The anti-inflammatory role of DHA and GW9508 is in part via activation of cPLA2 , COX-2 and production of PGE2 as a cPLA2 inhibitor or a COX-2 inhibitor partially reverses the DHA- and GW9508-induced inhibition of lipopolysaccharide-induced interleukin-6 secretion.	GW9508	38-44	prostaglandin-endoperoxide synthase 2	Mus musculus	82-87
24673159-6	2014	The anti-inflammatory role of DHA and GW9508 is in part via activation of cPLA2 , COX-2 and production of PGE2 as a cPLA2 inhibitor or a COX-2 inhibitor partially reverses the DHA- and GW9508-induced inhibition of lipopolysaccharide-induced interleukin-6 secretion.	GW9508	38-44	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	116-121
24673159-6	2014	The anti-inflammatory role of DHA and GW9508 is in part via activation of cPLA2 , COX-2 and production of PGE2 as a cPLA2 inhibitor or a COX-2 inhibitor partially reverses the DHA- and GW9508-induced inhibition of lipopolysaccharide-induced interleukin-6 secretion.	GW9508	38-44	prostaglandin-endoperoxide synthase 2	Mus musculus	137-142
24760994-7	2014	GW9508 (40 muM), an agonist of the FA receptor, G protein-coupled receptor 40 (GPR40), also increased calcium levels almost exclusively in FA-responsive neurons.	GW9508	0-6	free fatty acid receptor 1	Rattus norvegicus	48-77
24760994-7	2014	GW9508 (40 muM), an agonist of the FA receptor, G protein-coupled receptor 40 (GPR40), also increased calcium levels almost exclusively in FA-responsive neurons.	GW9508	0-6	free fatty acid receptor 1	Rattus norvegicus	79-84
24673159-3	2014	We report here that DHA and the GPR120 agonist, GW9508, activate cPLA2 and cyclooxygenase 2 (COX-2), and cause prostaglandin E2 (PGE2) release in a murine macrophage cell line RAW264.7 and in human primary monocyte-derived macrophages.	GW9508	48-54	free fatty acid receptor 4	Mus musculus	32-38
24673159-3	2014	We report here that DHA and the GPR120 agonist, GW9508, activate cPLA2 and cyclooxygenase 2 (COX-2), and cause prostaglandin E2 (PGE2) release in a murine macrophage cell line RAW264.7 and in human primary monocyte-derived macrophages.	GW9508	48-54	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	65-70
24673159-3	2014	We report here that DHA and the GPR120 agonist, GW9508, activate cPLA2 and cyclooxygenase 2 (COX-2), and cause prostaglandin E2 (PGE2) release in a murine macrophage cell line RAW264.7 and in human primary monocyte-derived macrophages.	GW9508	48-54	prostaglandin-endoperoxide synthase 2	Mus musculus	75-91
24673159-3	2014	We report here that DHA and the GPR120 agonist, GW9508, activate cPLA2 and cyclooxygenase 2 (COX-2), and cause prostaglandin E2 (PGE2) release in a murine macrophage cell line RAW264.7 and in human primary monocyte-derived macrophages.	GW9508	48-54	prostaglandin-endoperoxide synthase 2	Mus musculus	93-98
24734983-7	2014	The results showed that DHA, PD98059 (an ERK1/2 inhibitor), and GW9508 (a GPR120 agonist) inhibited VEGF-induced cell migration.	GW9508	64-70	vascular endothelial growth factor A	Homo sapiens	100-104
16702987-3	2006	Here, we present the first description of GW9508, a small-molecule agonist of the fatty acid receptors GPR40 and GPR120.	GW9508	42-48	free fatty acid receptor 1	Mus musculus	103-108
24758921-3	2014	A repeated but not a single intracerebroventricular administration of the GPR40 agonist, GW9508, reduced the duration of immobility behavior.	GW9508	89-95	free fatty acid receptor 1	Mus musculus	74-79
24349089-9	2013	The intracerebroventricular injection of DHA (50 microg) and GW9508 (1.0 microg), a GPR40-selective agonist, significantly reduced mechanical allodynia and thermal hyperalgesia at day 7, but not at day 1, after CFA injection.	GW9508	61-67	free fatty acid receptor 1	Mus musculus	84-89
24349089-11	2013	The protein expression of GPR40 was colocalized with that of beta-endorphin and proopiomelanocortin, and a single intracerebroventricular injection of GW9508 (1.0 microg) significantly increased the number of neurons double-stained for c-Fos and proopiomelanocortin in the arcuate nucleus of the hypothalamus.	GW9508	151-157	free fatty acid receptor 1	Mus musculus	26-31
24349089-11	2013	The protein expression of GPR40 was colocalized with that of beta-endorphin and proopiomelanocortin, and a single intracerebroventricular injection of GW9508 (1.0 microg) significantly increased the number of neurons double-stained for c-Fos and proopiomelanocortin in the arcuate nucleus of the hypothalamus.	GW9508	151-157	pro-opiomelanocortin-alpha	Mus musculus	61-75
24349089-11	2013	The protein expression of GPR40 was colocalized with that of beta-endorphin and proopiomelanocortin, and a single intracerebroventricular injection of GW9508 (1.0 microg) significantly increased the number of neurons double-stained for c-Fos and proopiomelanocortin in the arcuate nucleus of the hypothalamus.	GW9508	151-157	FBJ osteosarcoma oncogene	Mus musculus	236-241
23341496-0	2013	Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.	GW9508	23-30	free fatty acid receptor 1	Homo sapiens	44-73
23341496-3	2013	Therefore, we used a selective GPR40 agonist, GW-9508, to clarify the role of GPR40 in the regulation of blood glucose.	GW9508	46-53	free fatty acid receptor 1	Homo sapiens	31-36
23341496-4	2013	Bolus intraperitoneal injection of GW-9508 in mice showed a slight decrease in blood glucose, with an increase in plasma insulin levels under glucose stimuli.	GW9508	35-42	insulin	Homo sapiens	121-128
23341496-5	2013	However, long-term treatment with low doses of GW-9508 in high-fat diet-induced (HFD) diabetic mice decreased blood glucose with decreased plasma insulin significantly and improved glucose intolerance and insulin resistance.	GW9508	47-54	insulin	Homo sapiens	146-153
23341496-5	2013	However, long-term treatment with low doses of GW-9508 in high-fat diet-induced (HFD) diabetic mice decreased blood glucose with decreased plasma insulin significantly and improved glucose intolerance and insulin resistance.	GW9508	47-54	insulin	Homo sapiens	205-212
23341496-6	2013	Using small interfering ribonucleic acid to delete GPR40 in HepG2 cells, we demonstrated that GW-9508 reversed palmitate-induced insulin signaling impairment through a GPR40-dependent pathway.	GW9508	94-101	free fatty acid receptor 1	Homo sapiens	51-56
23341496-6	2013	Using small interfering ribonucleic acid to delete GPR40 in HepG2 cells, we demonstrated that GW-9508 reversed palmitate-induced insulin signaling impairment through a GPR40-dependent pathway.	GW9508	94-101	free fatty acid receptor 1	Homo sapiens	168-173
23341496-7	2013	We also found that GW-9508 activates the Akt/GSK-3beta pathway to increase glycogen levels in HepG2 cells.	GW9508	19-26	AKT serine/threonine kinase 1	Homo sapiens	41-44
23341496-7	2013	We also found that GW-9508 activates the Akt/GSK-3beta pathway to increase glycogen levels in HepG2 cells.	GW9508	19-26	glycogen synthase kinase 3 beta	Homo sapiens	45-54
23341496-8	2013	Furthermore, administration of GW-9508 decreased the hepatic expression of fetuin-A in HFD mice significantly and regulated high-glucose- or palmitate-induced fetuin-A expression to increase insulin sensitivity through a GPR40/PLC/PKC pathway in HepG2 cells.	GW9508	31-38	alpha-2-HS-glycoprotein	Mus musculus	75-83
23341496-8	2013	Furthermore, administration of GW-9508 decreased the hepatic expression of fetuin-A in HFD mice significantly and regulated high-glucose- or palmitate-induced fetuin-A expression to increase insulin sensitivity through a GPR40/PLC/PKC pathway in HepG2 cells.	GW9508	31-38	alpha-2-HS-glycoprotein	Mus musculus	159-167
23341496-8	2013	Furthermore, administration of GW-9508 decreased the hepatic expression of fetuin-A in HFD mice significantly and regulated high-glucose- or palmitate-induced fetuin-A expression to increase insulin sensitivity through a GPR40/PLC/PKC pathway in HepG2 cells.	GW9508	31-38	insulin	Homo sapiens	191-198
23341496-8	2013	Furthermore, administration of GW-9508 decreased the hepatic expression of fetuin-A in HFD mice significantly and regulated high-glucose- or palmitate-induced fetuin-A expression to increase insulin sensitivity through a GPR40/PLC/PKC pathway in HepG2 cells.	GW9508	31-38	free fatty acid receptor 1	Mus musculus	221-226
23341496-8	2013	Furthermore, administration of GW-9508 decreased the hepatic expression of fetuin-A in HFD mice significantly and regulated high-glucose- or palmitate-induced fetuin-A expression to increase insulin sensitivity through a GPR40/PLC/PKC pathway in HepG2 cells.	GW9508	31-38	perlecan (heparan sulfate proteoglycan 2)	Mus musculus	227-230
23335512-7	2013	In addition, in vivo administration of GW9508 counteracted ovariectomy-induced bone loss in wild-type but not GPR40(-/-) mice, enlightening the obligatory role of the GPR40 receptor.	GW9508	39-45	free fatty acid receptor 1	Mus musculus	167-172
23649389-13	2013	The beta-endorphin immunoreactivity in the brain increased at 10 and 20 min after intracerebroventricular injection of DHA and GW9508.	GW9508	127-133	proopiomelanocortin	Homo sapiens	4-18
21593768-0	2011	A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation.	GW9508	16-22	free fatty acid receptor 1	Homo sapiens	2-7
21593768-0	2011	A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation.	GW9508	16-22	C-C motif chemokine ligand 5	Homo sapiens	34-38
21593768-0	2011	A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation.	GW9508	16-22	C-C motif chemokine ligand 17	Homo sapiens	40-45
21593768-0	2011	A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation.	GW9508	16-22	C-X-C motif chemokine ligand 10	Homo sapiens	51-57
21593768-5	2011	Agonists for Gi-coupled receptors, particularly GW9508 for GPR40, inhibited CCL17 and CCL5 expression in a pertussis toxin-sensitive manner.	GW9508	48-54	free fatty acid receptor 1	Homo sapiens	59-64
21593768-5	2011	Agonists for Gi-coupled receptors, particularly GW9508 for GPR40, inhibited CCL17 and CCL5 expression in a pertussis toxin-sensitive manner.	GW9508	48-54	C-C motif chemokine ligand 17	Homo sapiens	76-81
21593768-5	2011	Agonists for Gi-coupled receptors, particularly GW9508 for GPR40, inhibited CCL17 and CCL5 expression in a pertussis toxin-sensitive manner.	GW9508	48-54	C-C motif chemokine ligand 5	Homo sapiens	86-90
21593768-6	2011	The inhibitory effect by GW9508 was abrogated by depletion of GPR40 with RNA interference.	GW9508	25-31	free fatty acid receptor 1	Homo sapiens	62-67
21593768-7	2011	GW9508 further suppressed expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-alpha and IFN-gamma.	GW9508	0-6	interleukin 11	Homo sapiens	40-45
21593768-7	2011	GW9508 further suppressed expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-alpha and IFN-gamma.	GW9508	0-6	interleukin 24	Homo sapiens	47-52
21593768-7	2011	GW9508 further suppressed expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-alpha and IFN-gamma.	GW9508	0-6	interleukin 33	Homo sapiens	58-63
21593768-7	2011	GW9508 further suppressed expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-alpha and IFN-gamma.	GW9508	0-6	tumor necrosis factor	Homo sapiens	90-99
21593768-7	2011	GW9508 further suppressed expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-alpha and IFN-gamma.	GW9508	0-6	interferon gamma	Homo sapiens	104-113
21593768-8	2011	GW9508 also inhibited CCL5 and CXCL10 production by normal human epidermal keratinocytes.	GW9508	0-6	C-C motif chemokine ligand 5	Homo sapiens	22-26
21593768-8	2011	GW9508 also inhibited CCL5 and CXCL10 production by normal human epidermal keratinocytes.	GW9508	0-6	C-X-C motif chemokine ligand 10	Homo sapiens	31-37
21593768-9	2011	Administration of GW9508 topically to the skin in the challenging phase suppressed ear swelling in a repeated hapten application model and contact hypersensitivity with downregulation of CCL5 and CXCL10, respectively.	GW9508	18-24	C-C motif chemokine ligand 5	Homo sapiens	187-191
21593768-9	2011	Administration of GW9508 topically to the skin in the challenging phase suppressed ear swelling in a repeated hapten application model and contact hypersensitivity with downregulation of CCL5 and CXCL10, respectively.	GW9508	18-24	C-X-C motif chemokine ligand 10	Homo sapiens	196-202
21575602-9	2011	The selective agonist of GPR40, GW9508, induced intracellular calcium mobilization and ERK2 phosphorylation.	GW9508	32-38	free fatty acid receptor 1	Homo sapiens	25-30
21575602-9	2011	The selective agonist of GPR40, GW9508, induced intracellular calcium mobilization and ERK2 phosphorylation.	GW9508	32-38	mitogen-activated protein kinase 1	Bos taurus	87-91
21334233-0	2011	Insight into analysis of interactions of GW9508 to wild-type and H86F and H137F GPR40: a combined QM/MM study and pharmacophore modeling.	GW9508	41-47	free fatty acid receptor 1	Homo sapiens	80-85
21334233-2	2011	In this work, a two-layered ONIOM based QM/MM approach was employed to study the interactions between GW9508 and GPR40: wild-type, H86F, and H137F mutated systems.	GW9508	102-108	free fatty acid receptor 1	Homo sapiens	113-118
19815053-3	2010	GW9508, a specific agonist of GPR40, significantly enhanced insulin secretion in the presence of high concentrations of glucose.	GW9508	0-6	free fatty acid receptor 1	Rattus norvegicus	30-35
24222669-5	2014	Addition of GW-9508 (a GPR120 chemical agonist) and alpha-linolenic acid (a natural ligand for GPR120) inhibited the secretion of ghrelin by ~50 and 70%, respectively.	GW9508	12-19	free fatty acid receptor 4	Mus musculus	23-29
24222669-5	2014	Addition of GW-9508 (a GPR120 chemical agonist) and alpha-linolenic acid (a natural ligand for GPR120) inhibited the secretion of ghrelin by ~50 and 70%, respectively.	GW9508	12-19	ghrelin	Mus musculus	130-137
24222669-8	2014	Moreover, we observed that the inhibitory effect of GW-9508 on ghrelin secretion was blocked by a small interfering RNA (siRNA) targeting the sequence of GPR120.	GW9508	52-59	ghrelin	Mus musculus	63-70
24222669-8	2014	Moreover, we observed that the inhibitory effect of GW-9508 on ghrelin secretion was blocked by a small interfering RNA (siRNA) targeting the sequence of GPR120.	GW9508	52-59	free fatty acid receptor 4	Mus musculus	154-160
24222669-9	2014	Furthermore, pretreatment with GW-9508 blocked the effect of the norepinephrine (NE)-induced ghrelin elevation in ghrelin cell lines.	GW9508	31-38	ghrelin	Mus musculus	93-100
24222669-9	2014	Furthermore, pretreatment with GW-9508 blocked the effect of the norepinephrine (NE)-induced ghrelin elevation in ghrelin cell lines.	GW9508	31-38	ghrelin	Mus musculus	114-121
24222669-10	2014	In addition, we showed that GW-9508 inhibited ghrelin secretion via extracellular signal-regulated kinase activity in ghrelin cell lines.	GW9508	28-35	ghrelin	Mus musculus	46-53
24222669-10	2014	In addition, we showed that GW-9508 inhibited ghrelin secretion via extracellular signal-regulated kinase activity in ghrelin cell lines.	GW9508	28-35	ghrelin	Mus musculus	118-125
23628491-1	2013	GW9508 is an agonist of G protein-coupled receptor 40 (GPR40) that is expressed in pancreatic beta-cells and is reported to regulate insulin secretion.	GW9508	0-6	free fatty acid receptor 1	Rattus norvegicus	24-53
23628491-1	2013	GW9508 is an agonist of G protein-coupled receptor 40 (GPR40) that is expressed in pancreatic beta-cells and is reported to regulate insulin secretion.	GW9508	0-6	free fatty acid receptor 1	Rattus norvegicus	55-60
23335512-6	2013	The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40(-/-) primary cell cultures.	GW9508	30-36	free fatty acid receptor 1	Mus musculus	4-9
23335512-6	2013	The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40(-/-) primary cell cultures.	GW9508	30-36	free fatty acid receptor 1	Mus musculus	105-110
22137657-7	2012	injection of DHA (25 and 50mug/mouse) and GW9508 (a GPR40- and GPR120-selective agonist; 0.1 and 1.0mug/mouse) significantly reduced formalin-induced pain behavior.	GW9508	42-48	free fatty acid receptor 1	Mus musculus	52-57
22137657-7	2012	injection of DHA (25 and 50mug/mouse) and GW9508 (a GPR40- and GPR120-selective agonist; 0.1 and 1.0mug/mouse) significantly reduced formalin-induced pain behavior.	GW9508	42-48	free fatty acid receptor 4	Mus musculus	63-69
21570468-6	2011	This resulted in a significant increase in the intracellular Ca2+ level, similar to the effect seen after treatment with the synthetic GPR40 agonist GW9508.	GW9508	149-155	free fatty acid receptor 1	Homo sapiens	135-140
19723586-9	2009	GW9508 had similar efficacy at the cynomolgus monkey and at the BC101175 human GPR120 receptors.	GW9508	0-6	free fatty acid receptor 4	Homo sapiens	79-85
17699519-9	2007	The greater number of putative interactions between GPR40 and GW9508 compared with linoleic acid may explain the higher potency of GW9508.	GW9508	131-137	free fatty acid receptor 1	Homo sapiens	52-57
16702987-3	2006	Here, we present the first description of GW9508, a small-molecule agonist of the fatty acid receptors GPR40 and GPR120.	GW9508	42-48	free fatty acid receptor 4	Mus musculus	113-119
16702987-7	2006	GW9508 and linoleic acid both stimulated intracellular Ca2+ mobilization in human embryonic kidney (HEK)293 cells expressing GPR40 (pEC50 values of 7.32+/-0.03 and 5.65+/-0.06, respectively) or GPR120 (pEC50 values of 5.46+/-0.09 and 5.89+/-0.04, respectively), but not in the parent HEK-293 cell line.	GW9508	0-6	free fatty acid receptor 1	Homo sapiens	125-130
16702987-7	2006	GW9508 and linoleic acid both stimulated intracellular Ca2+ mobilization in human embryonic kidney (HEK)293 cells expressing GPR40 (pEC50 values of 7.32+/-0.03 and 5.65+/-0.06, respectively) or GPR120 (pEC50 values of 5.46+/-0.09 and 5.89+/-0.04, respectively), but not in the parent HEK-293 cell line.	GW9508	0-6	free fatty acid receptor 4	Homo sapiens	194-200
16702987-9	2006	GW1100 dose dependently inhibited GPR40-mediated Ca2+ elevations stimulated by GW9508 and linoleic acid (pIC50 values of 5.99+/-0.03 and 5.99+/-0.06, respectively).	GW9508	79-85	free fatty acid receptor 1	Mus musculus	34-39
34297968-5	2021	The results revealed that intragastric administrated GW9508 could significantly ameliorate cognitive deficits of AD mouse, up-regulate the expression levels of gut-brain peptides both in blood circulation and hypothalamus thus up-regulate the expression levels of alpha-MSH in hypothalamus, while the negative autophagy-related proteins and inflammation-related proteins were down-regulated correspondingly.	GW9508	53-59	STAM binding protein	Mus musculus	264-273
34297968-3	2021	GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy.	GW9508	14-20	free fatty acid receptor 1	Mus musculus	0-5
25362997-9	2015	injection of GW9508, a FFA1 receptor agonist, increased the number of c-Fos-positive cells and the number of neurons double-labelled for c-Fos and TPH and/or DBH.	GW9508	13-19	FBJ osteosarcoma oncogene	Mus musculus	70-75
25362997-9	2015	injection of GW9508, a FFA1 receptor agonist, increased the number of c-Fos-positive cells and the number of neurons double-labelled for c-Fos and TPH and/or DBH.	GW9508	13-19	FBJ osteosarcoma oncogene	Mus musculus	137-142
25362997-9	2015	injection of GW9508, a FFA1 receptor agonist, increased the number of c-Fos-positive cells and the number of neurons double-labelled for c-Fos and TPH and/or DBH.	GW9508	13-19	tryptophan hydroxylase 1	Mus musculus	147-150
25362997-9	2015	injection of GW9508, a FFA1 receptor agonist, increased the number of c-Fos-positive cells and the number of neurons double-labelled for c-Fos and TPH and/or DBH.	GW9508	13-19	dopamine beta hydroxylase	Mus musculus	158-161
34297968-3	2021	GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy.	GW9508	14-20	free fatty acid receptor 1	Mus musculus	95-100
34297968-3	2021	GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy.	GW9508	14-20	free fatty acid receptor 1	Mus musculus	194-199
34489696-6	2021	Interestingly, local application of a FFAR1 agonist, GW9508, markedly augmented the striatal 5-HT release in FFAR1 wild-type (+/+) mice, whereas topical application of a FFAR1 antagonist, GW1100, significantly reduced the 5-HT release.	GW9508	53-59	free fatty acid receptor 1	Mus musculus	38-43
34275493-6	2021	GPR40 agonist, GW9508, was administered intranasally 1 h, 25 h, and 49 h after GMH induction.	GW9508	15-21	free fatty acid receptor 1	Rattus norvegicus	0-5
34275493-12	2021	GW9508 upregulated the phosphorylation of PAK4, CREB, and protein level of KDM6B, CD206, IL-10, which was also met with the downregulation of inflammatory markers IL-1beta and TNF-alpha.	GW9508	0-6	p21 (RAC1) activated kinase 4	Rattus norvegicus	42-46
34275493-12	2021	GW9508 upregulated the phosphorylation of PAK4, CREB, and protein level of KDM6B, CD206, IL-10, which was also met with the downregulation of inflammatory markers IL-1beta and TNF-alpha.	GW9508	0-6	cAMP responsive element binding protein 1	Rattus norvegicus	48-52
34275493-12	2021	GW9508 upregulated the phosphorylation of PAK4, CREB, and protein level of KDM6B, CD206, IL-10, which was also met with the downregulation of inflammatory markers IL-1beta and TNF-alpha.	GW9508	0-6	lysine demethylase 6B	Rattus norvegicus	75-80
34275493-12	2021	GW9508 upregulated the phosphorylation of PAK4, CREB, and protein level of KDM6B, CD206, IL-10, which was also met with the downregulation of inflammatory markers IL-1beta and TNF-alpha.	GW9508	0-6	interleukin 10	Rattus norvegicus	89-94
34275493-12	2021	GW9508 upregulated the phosphorylation of PAK4, CREB, and protein level of KDM6B, CD206, IL-10, which was also met with the downregulation of inflammatory markers IL-1beta and TNF-alpha.	GW9508	0-6	interleukin 1 alpha	Rattus norvegicus	163-171
34275493-12	2021	GW9508 upregulated the phosphorylation of PAK4, CREB, and protein level of KDM6B, CD206, IL-10, which was also met with the downregulation of inflammatory markers IL-1beta and TNF-alpha.	GW9508	0-6	tumor necrosis factor	Rattus norvegicus	176-185
34275493-13	2021	The mechanism study demonstrated that the knockdown of GPR40, PAK4, and KDM6B reversed the neuroprotective effects brought on by GW9508.	GW9508	129-135	free fatty acid receptor 1	Rattus norvegicus	55-60
34275493-13	2021	The mechanism study demonstrated that the knockdown of GPR40, PAK4, and KDM6B reversed the neuroprotective effects brought on by GW9508.	GW9508	129-135	p21 (RAC1) activated kinase 4	Rattus norvegicus	62-66
34275493-13	2021	The mechanism study demonstrated that the knockdown of GPR40, PAK4, and KDM6B reversed the neuroprotective effects brought on by GW9508.	GW9508	129-135	lysine demethylase 6B	Rattus norvegicus	72-77
34489696-6	2021	Interestingly, local application of a FFAR1 agonist, GW9508, markedly augmented the striatal 5-HT release in FFAR1 wild-type (+/+) mice, whereas topical application of a FFAR1 antagonist, GW1100, significantly reduced the 5-HT release.	GW9508	53-59	free fatty acid receptor 1	Mus musculus	109-114
35584771-10	2022	GW9508 can attenuate inflammation by reducing the expression of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 under HG.	GW9508	0-6	NLR family pyrin domain containing 3	Homo sapiens	64-69
35584771-10	2022	GW9508 can attenuate inflammation by reducing the expression of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 under HG.	GW9508	0-6	PYD and CARD domain containing	Homo sapiens	71-74
35584771-10	2022	GW9508 can attenuate inflammation by reducing the expression of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 under HG.	GW9508	0-6	caspase 1	Homo sapiens	76-85
35584771-10	2022	GW9508 can attenuate inflammation by reducing the expression of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 under HG.	GW9508	0-6	interleukin 1 alpha	Homo sapiens	87-95
35584771-10	2022	GW9508 can attenuate inflammation by reducing the expression of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 under HG.	GW9508	0-6	interleukin 18	Homo sapiens	101-106
35584771-11	2022	GW9508 rescues the viability of HRMCs and reduces cell apoptosis by preventing an increase in Bax expression and the reduction in Bcl-2 expression.	GW9508	0-6	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97
35584771-11	2022	GW9508 rescues the viability of HRMCs and reduces cell apoptosis by preventing an increase in Bax expression and the reduction in Bcl-2 expression.	GW9508	0-6	BCL2 apoptosis regulator	Homo sapiens	130-135
35584771-12	2022	Additionally, knockdown of GPR120 by siRNA weakened the effects of GW9508 on NLRP3 inflammasome expression.	GW9508	67-73	free fatty acid receptor 4	Homo sapiens	27-33
35584771-12	2022	Additionally, knockdown of GPR120 by siRNA weakened the effects of GW9508 on NLRP3 inflammasome expression.	GW9508	67-73	NLR family pyrin domain containing 3	Homo sapiens	77-82
35061031-9	2022	Importantly, the GPR40 agonist GW9508 reverted established diabetesinduced hypersensitivity, an effect which was blocked by VEGF-A administration.	GW9508	31-37	free fatty acid receptor 1	Homo sapiens	17-22
35061031-9	2022	Importantly, the GPR40 agonist GW9508 reverted established diabetesinduced hypersensitivity, an effect which was blocked by VEGF-A administration.	GW9508	31-37	vascular endothelial growth factor A	Homo sapiens	124-130